Lakewood-Amedex Biotherapeutics, Inc. (LABT)
Lakewood-Amedex Biotherapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in University Park, FL, US. The stock last traded at $1.67, down 8.49% on the session, giving a market capitalisation of $2.9M. On trailing twelve-month figures it carries a trailing P/E of -0.17, a net margin of 0.0%. Its beta of -4.76 implies it has historically moved less than the broad market.
Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.